The natural history and pathophysiology of treatment resistant schizophrenia

Journal of Psychiatric Research

Volumn 32, Issue 3-4, 1998, Pages 143-150

  Sheitman, B B ^a,b   Lieberman, J A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Dorothea Dix Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; NEUROLEPTIC AGENT;

CORPUS STRIATUM; DETERIORATION; DISEASE DURATION; DOPAMINE RELEASE; EARLY DIAGNOSIS; HUMAN; MORBIDITY; NEUROCHEMISTRY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; SCHIZOPHRENIA; SENSITIZATION; TREATMENT OUTCOME;

EID: 0032073383     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3956(97)00052-6     Document Type: Article

References (71)

1. Akbarian S, Bunney WE Jr, Potkin SG, Wigal SB, Hagman JO, Sandman CA, Jones EG. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry 1993a;50(3):169-77.
2. Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE Jr, Jones EG. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 1995;52:258-65.
3. Akbarian S, Vinuela A, Kim JJ, Potkin SG, Bunney WE Jr, Jones EG. Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch Gen Psychiatry 1993b;50(3):178-87.
4. Alvir JMJ. Woerner MG, Gunduz H, Lieberman JA, Obstetric complications predict treatment response in first episode schizophrenia (abstract). VI International Congress of Schizophrenia Research, Warm Springs, VA., 1997.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition. Washington, D.C., 1994.
6. Bloom FE. Advancing a neurodevelopmental origin for schizophrenia. Arch Gen Psychiatry 1993;50(3):224-7.
7. Bogerts B. Recent advances in the neuropathology of schizophrenia. Schizophr Bull 1993;19(2):431-45.
8. Bracha HS, Torrey EF, Bigelow LB, Lohr JB, Linington BB. Subtle signs of prenatal maldevelopment of the hand ectoderm in schizophrenia: A preliminary monozygotic twin study. Biol Psychiatry 1991;30:719-25.
9. Breier A, Su T-P, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci 1997;94:2569-74.
10. Brenner HD, Dencker SJ, Goldstein MJ, Hubbard JW, Keegan DL, Kruger G, Kulhanek F, Liberman RP, Malm U, Midha KK. Defining treatment refractoriness in schizophrenia. Schizophr Bull 1990;16(4), 551-60.
11. Bunney BS, Grace AA. Acute and chronic heloperidol treatment: comparison of effects on nigral dopaminergic cell activity. Life Sci 1978;23:1715-28.
12. Chakos MH, Alvir JMJ, Woerner MG, Koreen A, Geisler S, Mayerhoff D, Sobel S, Kane JM, Borenstein M, Lieberman JA. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry, 1996;53(4):313-9.
13. Charney DS, Deutch AY, Krystal JH, Southwick SM, Davis M. Psychobiologic mechanisms of posttraumatic stress disorder. Arch Gen Psychiatry 1993;50:294-305.
14. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192:480-3.
15. Crow TJ, MacMillan TF, Johnson AL, et al. A randomized controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986;148:120-7.
16. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry, 1991;148(11):1474-86.
17. Degreef G, Bogerts B, Fallea P, Greve B, Lantos G, Ashtari M, Lieberman J. Increased prevalence of the cavum septum pellucidum in magnetic resonance scans and post-mortem brains of schizophrenic patients. Psychiatry Research 1992;45(1):1-13.
18. DeLisi LE, Hoff AL, Schwartz JE, Shields GW, Halthore SN, Gupta SM, Henn FA, Anand AK. Brain morphology in first-episode schizophrenic-like psychotic patients: a quantitative magnetic resonance imaging study. Biol Psychiatry 1991;29(2):159-75.
19. DeLisi LE, Crimson R, Sekume M, Tew W, Rushner M, Hoff AL. Schizophrenia as a chronic active brain process: A study of progressive brain structural change subsequent to the onset of schizophrenia. In press.
20. Done DJ, Crow TJ, Johnstone EC, Sacker A. Childhood antecedents of schizophrenia and affective illness: social adjustment at ages 7 and 11. BMJ 1994;309:699-703.
21. Falloon IRH, Kydd RR, Coverdale JH, Laidlaw TM. Early detection and intervention for initial episodes of schizophrenia. Schizophr Bull 1996;22(2):271-82.
22. Feinberg I. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? J Psychiatr Res 1982;17:319-34.
23. Fish B. Neurobiologic antecedents of schizophrenia in children: Evidence for an inherited, congenital neurointegrative defect. Arch Gen Psychiatry 1977;34, 1297-1313.
24. Giron B, Jaber M, Wightman RM, Caron M. Hyperlocomotion and indifference to cocaine and amphetamines in mice lacking the dopamine transporter. Nature 1996;379:606-12.
25. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991;41(1):1-24.
26. Grace AA. The tonic/phasic model of dopamine system regulation: Its relevance for understanding how stimulant abuse can alter basal ganglia function. Drug Alcohol Depend 1995;37:111-29.
27. Gur RE, Mozky D, Resnick S, Moseley L, Shastel D, Gallacher R, Arnold S, Karp J, Alari A, Revich M, Gur RC. Resting cerebral glucose metabolism in first-episode and treated patients with schizophrenia. Arch Gen Psychiatry 1995:52:657-67.
28. Huttenlocher PR. Synaptic density in the human frontal cortex - developmental changes and the effects of aging. Brain Res 1979;163:195-205.
29. Illowsky BP, Juliano DM, Migelow LB, Weinberger DR. Stability of CT scan findings in schizophrenia: results of an 8 year follow-up study. J Neurol Neurosurg Psychiatry 1998;51(2):209-13.
30. Jakob H, Beckmann H. Prenatal developmental disturbances in the limbic allocortex in schizophrenics. J Neural Transm 1986;65(3-4):303-26.
31. Kalivas PW, Stewart J. Dopamine transmission in the initiation and expression of drug and stress induced sensitization of motor activity. Brain Res Rev 1991;16:223-44.
32. Kane J, Honigfeld G, Singer J, Meltzer HY. Is clozapine response different in neuroleptic nonresponders vs partial responders: In reply. Arch Gen Psychiatry 1991;47:189-90.
33. Kovelman JA, Scheibel AB. A neurohistological correlate of schizophrenia. Biol Psychiatry 1984;19(12):1601-21.
34. Kraepelin, E. Dementia Praecox and Paraphrenia. (1919) Edited by Barkley, R.M., Robertson, G.M. Edinburgh, Scotland:E.and S. Livingstone. 1971.
35. Laruelle M, Abi-Dargham A, Van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci 1996;93(17):9235-40.
36. Li L, Chin L-S, Shupliakov O, Brodin L, Sihra TS, Hvalby O, Jensen V, Zheng D, McNamara JO, Greengard P, Andersen P. Impairment of synaptic vesicle clustering and of synaptic transmission, and increased seizure propensity, synapsin I-deficient mice. Proc Natl Acad Sci 1995;92:9235-9.
37. Lieberman J, Alvir JM, Koreen A, Geisler S, Chakos M, Sheitman B, Woerner M. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology, 1996;14(3S):13S-21S.
38. Lieberman, J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, Woerner M, Borenstein M. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993;50:369-75.
39. Lieberman JA, Alvir J, Geisler S, Ramos-Lorenzi J, Woerner M, Novacenko H, Cooper T, Kane JM. Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia. Neuropsychopharmacology 1994;11(2):107-18.
40. Lieberman JA, Kane JM, Alvir JAJ. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology, 1987;91:415-33.
41. Lieberman JA, Kinon BJ, Loebel AD. Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schizophr Bull 1990;16(1):97-109.
42. Lieberman JA, Sheitman BB, Kinon BJ. Endogenous neurochemical sensitization in the pathophysiology of schizophrenia deficits and dysfunction in neuronol regulation and plasticity. Neuropsychopharmacology, In press.
43. Loebel AD, Lieberman JA, Alvir JMJ, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992;149(9):1183-1188.
44. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151(6), 825-35.
45. May PR, Tuma AH, Dixon WJ. Schizophrenia: a follow-up study of the results of five forms of treatment. Arch Gen Psychiatry 1981;38:776-84.
46. McGlashan TH, Fenton WS. Subtype Progression and Pathophysiologic Deterioration in Early Schizophrenia. Schizophr Bull 1993;19(1):71-84.
47. McGlashan TH, Johannessen JO. Early detection and intervention with schizophrenia: rationale. Schizophr Bull 1996;22(2):201-22.
48. Meltzer H. Commentary: Defining treatment refractoriness in schizophrenia. Schizophr Bull 1990;16(4):563-5.
49. Meltzer HY, Stahl SM. The dopamine hypothesis of schizophrenia: A review. Schizophr Bull 1976;2:19-76.
50. Murray RM. Neurodevelopmental schizophrenia: The rediscovery of dementia praecox. Br J Psychiatry, Supplement 1994;25:6-12.
51. Murray RM, O'Callaghan E, Castle DJ, Lewis SW. A neurodevelopmental approach to the classification of schizophrenia. Schizophr Bull 1992;18(2):319-32.
52. Nasrallah HA, Olson SC, McCalley-Whitters M, Chapman S, Jacoby OG. Cerebral ventricular enlargement in schizophrenia: a preliminary follow-up study. Arch Gen Psychiatry 1986;43:157-9.
53. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995;52:998-1007.
54. Post RM, Kopanda RT. Cocaine, kindling, and Psychosis. Am J Psychiatry 1976;133(6):627-34.
55. Rapoport JL, Giedd J, Alaghband-Rad J, Jacobsen L, Kumra S, Lenane M. Accelerated increase brain ventricular volume at 2-year rescan for childhood onset schizophrenics (abstract). VI International Congress of Schizophrenia Research, Warm Springs, VA, 1997.
56. Safferman A, Lieberman J, Kane J, Szymanski S, Kinon B. Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 1991;17(2):247-61.
57. Sato M, Numachi Y, Hamamura T. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophr Bull 1992;18:115-22.
58. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976;261:717-9.
59. Sham PC, Castle DJ, Wessely S, Farmer AE, Murray RM. Further exploration of a latent class typology of schizophrenia. Schizophrenia Research 1996;20(1-2):105-15.
60. Snyder SH, Banerjee SP, Yamamura HI, Greenberg D. Drugs, neurotransmitters, and schizophrenia. Science 1974;184:1243-53.
61. Stevens JR. Psychiatric aspects of epilepsy. J. Clin Psychiatry Suppl. 1988;49:49-57.
62. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME. Olanzapine Versus Haloperidol in the Treatment of Schizophrenia and Schizoaffective and Schizophreniform Disorders: Results of an International Collaborative Trial. Am J Psychiatry 1997;154:457-65.
63. Torrey, EF in collaboration with Bowler AE, Talor EH, Gottesman II. Schizophrenia and manic-depressive disorder: the biological roots of mental illness as revealed by the landmark study of identical twins. NY: BasicBooks, 1994.
64. Von Voightlander PF, Moore KE. Involvement of nigrostriatal neurons in the in vivo release of dopamine by amphetamine, amantadine, and tyramine. J Pharmacol Exp Ther 1971;194:542-52.
65. Walker E, Lewine RJ. Prediction of adult-onset schizophrenia from childhood home movies of the patients. Am J Psychiatry 1990;147(8):1052-6.
66. Watt NF. Patterns of childhood social development in adult schizophrenics. Arch Gen Psychiatry 1978;35: 160-5.
67. Weinberger DR. Computed tomography (CT) findings in schizophrenia: speculation on the meaning of it all. J Psychiatr Res 1984;18(4):477-90.
68. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44:660-9.
69. Woods BT, Yurgelun-TD, Benes FM, Frankenbury FR, Pope HG, McSparren J. Progressive ventricular enlargement in schizophrenia: comparison to bipolar affective disorder and correlation with clinical course. Biol Psychiatry 1990;27:341-52.
70. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991;17(2):325-51.
71. Zubin, J, Spring, B. Vulnerability - a new view of schizophrenia. J Abn Psychology 1997;86(2):103-26.